PHVS ▲ +16.9% - Pharvaris N.V. $PHVS - Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks Pharvaris shares surged 16.9% following the company's announcement of positive topline results from its CHAPTER-3 pivotal trial evaluating deucrictibant XR as a preventive treatment for hereditary angioedema (HAE) attacks. The successful Phase 3 data represents a key milestone for the lead candidate and supports the company's path toward regulatory approval in this rare disease indication. 08-SEP-2026 06:50 AM ET